BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

Mimetas

Mimetas logo

Website
http://mimetas.com/
Founded
2013
Patents
10
Publications
66

Mimetas is a Dutch company based in Leiden, which specializes in developing organ-on-a-chip models for drug development. Founded in 2013, they raised $32.4M from multiple investors.

The company provides OrganoServices for compound profiling or screening in the human-relative models. Combined with their OrganoPlates, the screening can be performed for multiple compounds using just one plate.


Posts Mentioning This Company

How Industry Embraces Organ-on-Chips: A 2024 Status Report

April 17, 2024  
Report highlights: We are currently at an exciting juncture where several big pharmaceutical companies have started adopting such models and conducted several exploratory studies The last 4 years have witnessed at least twofold increase in industrial validation of organ-on-chips across various fields and organ models The majority of the studies …

MIMETAS' Recent Milestones in Advancing Drug Discovery Through Organ-on-a-Chip Technology

March 28, 2023  
As the pharmaceutical industry seeks innovative solutions for preclinical development, organ-on-a-chip technology has gained significant traction in recent years. This groundbreaking approach, which emerged in the early 2000s, involves the creation of miniaturized, three-dimensional cell cultures that replicate human organ function within microfluidic devices. These devices, composed of intricate networks …
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

Mimetas has such essential models as blood vessel integrity, angiogenesis and blood-brain-barrier toxicity and small molecule transport. Their proprietary OrganoFlow platform drives precisely-controlled perfusion flow in the OrganoPlate, simulating the physiological conditions.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.